Side-by-side · Research reference

5-Amino-1MQvsAOD-9604

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BPhase 2Reviewed10/47 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2008

~30 minHalf-life

SQ · Abdomen · Daily fasted

01Mechanism of Action

Parameter

5-Amino-1MQ

AOD-9604

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

β3-adrenergic receptor (proposed)Ng 2008

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Feedback intact?

—

No GH-axis or IGF-1 feedback

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

AOD-9604

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

Frequency

Once daily, fasted

Lower / starter dose

50 mg / day

150 mcg / day

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Phase 2 trials + animal-strongHeffernan 2001 Ng 2008

Duration

8–12 weeks per cycle

Form

Oral capsule

—

Timing

Morning fasted preferred

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

Half-life

Hours (estimated; no human PK published)

~30 min plasma

Reconstitution

—

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

04Side Effects & Safety

Parameter

5-Amino-1MQ

AOD-9604

GI symptoms

Mild nausea (anecdotal)

Rare mild nausea

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

Pregnancy / OB

Avoid

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Injection site reaction

—

Mild erythema

Cardiovascular

—

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

IGF-1 elevation

—

None — designed to lack GH-axis activityHeffernan 2001

Insulin sensitivity

—

Neutral — no glucose impairmentHeffernan 2001

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

05Administration Protocol

Parameter

5-Amino-1MQ

AOD-9604

1. Form

Oral capsule. No injection.

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

2. Administration

Take with water, fasted preferred.

SQ — abdomen preferred. Rotate sites.

3. Timing

Morning fasted.

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Caveat

Monitor B-vitamin status with chronic use.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

5-Amino-1MQ

— no documented stacks

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern